BOSTON--(BUSINESS WIRE)--Click to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced the appointment of Kathie Lindemann as its Chief Operating Officer, reporting to Christoph Westphal M.D., Ph.D., Flex Pharma’s President, CEO and Chair.
Help employers find you! Check out all the jobs and post your resume.
